Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report.

Abstract

RATIONALE:

In estrogen receptor-positive HER2-negative (ER+HER2-) metastatic breast cancer, chemotherapy should be offered only to patients who develop endocrine resistance or have a rapid disease progression. However, the correct sequence of chemotherapy administration is still debated.

PATIENT CONCERNS:

We report the case of a 49-year-old woman with ER+ HER2- metastatic breast cancer who experienced an exceptionally long response to capecitabine administered as second-line therapy following a first-line anthracycline-based chemotherapy.

DIAGNOSES:

The patient was diagnosed with ER+ HER2- metastatic breast cancer with massive liver involvement and mediastinal lymph nodes metastasis.

INTERVENTIONS:

This patient was treated with capecitabine 1000 mg/mq bid given intermittently for 14 days within a 21-day cycle as a second-line therapy following a rapid progression on letrozole treatment given as a maintenance therapy.

OUTCOMES:

Our patient experienced a progression-free survival (PFS) >3 years with an exceptionally good quality of life (QoL).

LESSONS:

In ER+HER2- metastatic breast cancer patients, capecitabine monochemotherapy in second line may be associated with a particularly satisfactory PFS and no impact in terms of QoL. Future studies focused on biomarkers with predictive ability may help select patients who represent the best candidates to this treatment.

• Authors: Giacomo Barchiesi, Eriseld Krasniqi, Maddalena Barba, Marina Della Giulia, Laura Pizzuti, Gioia Massimiani, Gennaro Ciliberto, Patrizia Vici
• Journal: Medicine (Medicine (Baltimore)) Vol. 98 Issue 37 Pg. e17135 (Sep 2019) ISSN: 1536-5964 [Electronic] United States
• PMID: 31517852 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Receptors, Estrogen
• Capecitabine

Topics

• Antimetabolites, Antineoplastic (therapeutic use)
• Breast Neoplasms (drug therapy, genetics, pathology)
• Capecitabine (therapeutic use)
• Carcinoma, Ductal, Breast (drug therapy, genetics, pathology)
• Female
• Humans
• Liver Neoplasms (drug therapy, secondary)
• Lymphatic Metastasis (genetics)
• Middle Aged
• Receptors, Estrogen (genetics)